Classification of Genes Based on Age-Related Differential Expression in Breast Cancer

Transcriptome analysis has been widely used to make biomarker panels to diagnose cancers. In breast cancer, the age of the patient has been known to be associated with clinical features. As clinical transcriptome data have accumulated significantly, we classified all human genes based on age-specific differential expression between normal and breast cancer cells using public data. We retrieved the values for gene expression levels in breast cancer and matched normal cells from The Cancer Genome Atlas. We divided genes into two classes by paired t test without considering age in the first classification. We carried out a secondary classification of genes for each class into eight groups, based on the patterns of the p-values, which were calculated for each of the three age groups we defined. Through this two-step classification, gene expression was eventually grouped into 16 classes. We showed that this classification method could be applied to establish a more accurate prediction model to diagnose breast cancer by comparing the performance of prediction models with different combinations of genes. We expect that our scheme of classification could be used for other types of cancer data.

[1]  L. Holmberg,et al.  Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment , 2009, PloS one.

[2]  Ryan D. Morin,et al.  Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. , 2008, BioTechniques.

[3]  M. A. Chung,et al.  Elevated Breast Cancer Mortality in Women Younger than Age 40 Years Compared with Older Women Is Attributed to Poorer Survival in Early-Stage Disease , 2009 .

[4]  R. Tibshirani,et al.  Empirical bayes methods and false discovery rates for microarrays , 2002, Genetic epidemiology.

[5]  C. Sotiriou,et al.  Genomic aberrations in young and elderly breast cancer patients , 2015, BMC Medicine.

[6]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[8]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[9]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[10]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[11]  A. Psyrri,et al.  Beyond BRCA: new hereditary breast cancer susceptibility genes. , 2015, Cancer treatment reviews.

[12]  Elias Campo Guerri,et al.  International network of cancer genome projects , 2010 .

[13]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[14]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[15]  G. Hortobagyi,et al.  Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer , 2006, Nature Clinical Practice Oncology.

[16]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[17]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[18]  P. Khatri,et al.  Global functional profiling of gene expression. , 2003, Genomics.

[19]  Jing Chen,et al.  ToppGene Suite for gene list enrichment analysis and candidate gene prioritization , 2009, Nucleic Acids Res..